A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers

Por León-Cachón, Rafael B. R., Ascacio-Martínez, Jorge A., Gamino-Peña, María E., Cerda-Flores, Ricardo M., Meester, Irene, Gallardo-Blanco, Hugo L., Gómez-Silva, Magdalena, Piñeyro-Garza, Everardo, Barrera-Saldaña, Hugo A.
Publicado no BMC Cancer (2016)